Moussa B. Youdim

P.O.Box 620, New Industrial Park
Yokneam, 20692, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3 ligase component, SKP1A.

A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3 ligase component, SKP1A.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: April 28, 2023

Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson's disease.

Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson's disease.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: March 13, 2023

The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.

The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: January 10, 2023

The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.

The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.

Journal: Cells

Published: October 24, 2022

Correction to: Lithium's Gene Expression Profile, Relevance to Neuroprotection A cDNA Microarray Study.

Correction to: Lithium's Gene Expression Profile, Relevance to Neuroprotection A cDNA Microarray Study.

Journal: Cellular and molecular neurobiology

Published: August 22, 2022

Treatment; Moussa B.H. Youdim.

Treatment; Moussa B.H. Youdim.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: March 13, 2022

Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer's disease therapy.

Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer's disease therapy.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: September 30, 2021

The protective, rescue and therapeutic potential of multi-target iron-chelators for retinitis pigmentosa.

The protective, rescue and therapeutic potential of multi-target iron-chelators for retinitis pigmentosa.

Journal: Free radical biology & medicine

Published: May 15, 2021

Creation of a gene expression classifier for predicting Parkinson's disease rate of progression.

Creation of a gene expression classifier for predicting Parkinson's disease rate of progression.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: February 21, 2020

Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.

Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: August 27, 2018

A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist.

A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist.

Journal: Purinergic signalling

Published: March 26, 2018

Iron-Chelating Drugs Enhance Cone Photoreceptor Survival in a Mouse Model of Retinitis Pigmentosa.

Iron-Chelating Drugs Enhance Cone Photoreceptor Survival in a Mouse Model of Retinitis Pigmentosa.

Journal: Investigative ophthalmology & visual science

Published: October 20, 2017

Showing 1-12 of 93

Last Updated: 09/26/2026